PATH names Steve Davis as president and CEO

 PATH announced that Steve Davis was appointed president and CEO, noting that Mr. Davis “brings leadership experience in numerous innovation-focused organizations, both nonprofit and for-profit, and has worked extensively in emerging economies throughout his career.” He comes to PATH most recently from McKinsey & Company, where he was global director of social innovation. Dr. Molly Joel Coye, chair of PATH’s board of directors, said, “We are delighted to have Steve bring his extensive global health and development expertise and insight to PATH. Steve brings a history with PATH as a previous board member and is a proven innovator and versatile leader with a longstanding commitment to social change. His deep knowledge of health needs in the developing world and impressive accomplishments in creating solutions tailored for the communities where PATH works immediately stood out among our extraordinarily high-caliber pool of applicants.” Mr. Davis commented, “I have long admired PATH for its spirit of innovation and its tremendous strides in addressing inequities and saving lives around the world. My work always has been fueled by a passion for creating genuine social impact with leading-edge innovations, and I am honored to join such a prominent and effective organization, to continue PATH’s powerful work in global health, and to advance the delivery of sustainable impact.” PATH noted that Mr. Davis will oversee an annual budget of US$305 million, a staff of nearly 1,200, and a robust portfolio of projects based in PATH offices in 22 countries.

MMWR: Prevalence of Autism Spectrum Disorders – 2008

   MMWR Surveillance Summaries; March 30, 2012 / Vol. 61 / No. SS–3
Prevalence of Autism Spectrum Disorders — Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008
This report provides updated autism spectrum disorder (ASD) prevalence estimates from the 2008 surveillance year, representing 14 Autism and Developmental Disabilities Monitoring (ADDM) sites in the United States. For 2008, the overall estimated prevalence of ASDs among the 14 ADDM sites was 11.3 per 1,000 (one in 88) children aged 8 years who were living in these communities during 2008. The extent to which these increases reflect better case ascertainment as a result of increases in awareness and access to services or true increases in prevalence of ASD symptoms is not known.

PAHO to launch Regional Platform for Access to Health Technologies and Innovation

PAHO said it will launch the Regional Platform for Access to Health Technologies and Innovation in early May, an initiative “to improve transparency, information flow, and cooperation among countries of the region in order to promote access, innovation, rational use, and governance of essential drugs, biological medicines, and diagnostics in public health.” PAHO noted that the interactive platform “encompasses research, development, and innovation for health technologies; pharmaceutical policies and health technologies; access to and rational use of medicines; and regulation and management of intellectual property. It is a tool for health authorities in the Americas; national regulatory authorities; departments of science, technology, and innovation; scientists, researchers, and research institutes; civil society, nongovernmental organizations, and foundations that work with medicines and health technologies; and sectors of the pharmaceutical industry. The new platform offers a series of virtual tools, including:

– Communities to Share Practices: This instrument enables people and institutions to work together to share and create knowledge about common interests.

– Innovation Forum: The forum is an opportunity to collaborate on solving problems related to health innovations.

– Annotated List of Medicines: This tool contains information on the essential and strategic drugs in use in the region, and will make it possible to examine the list of essential drugs of countries, evidence summaries, and the regulatory status of health technologies.

– Observatory: This instrument provides information on the sectors and processes involved in the development, production, and regulation of health technologies through the use of standardized and periodically updated indicators.

Meeting: WHO SAGE 10-12 April 2012, Geneva – Agenda

Meeting: WHO SAGE
10-12 April 2012, Geneva
Draft agenda (as of 22 March 2012)

Agenda Sessions:
–          Report from Director, IVB

–          Polio Eradication

–          Seasonal influenza vaccine

–          Impact of introduction of new vaccines on the strengthening of immunization and health systems

–          Vaccination in humanitarian emergencies

–          Rotavirus vaccines schedules

–          Use of hepatitis A vaccines

–          Report from the GAVI Alliance Secretariat

–          Information on vaccines for an Intergovernmental Negotiating Committee on Mercury

WHO: Immunization highlights – 2011

WHO: Immunization highlights – 2011
In 2011, there was important progress in a number of areas. About 180 countries across five WHO regions celebrated Immunization Week and the first official WHO-supported World Hepatitis Day was held to increase awareness and understanding of viral hepatitis and the diseases that it causes. The demand for new and underused vaccines is rising and more countries are introducing vaccines against meningococcal A epidemics, pneumococcal disease and rotavirus. A selection of the most notable immunization achievements and events of 2011 is featured here, together with data based on the latest WHO/UNICEF global estimates for 2010.